JCRI-ABTS and USMI Reports Statistically Significant Results of the Canady Helios Cold Plasma Phase 1 Clinical Trial on Patients with Stage 4 and Recurrent Advanced Solid Tumors by Admin-USMI | Jun 15, 2023 | News Release 2023Takoma Park, MDRead Press...
US Medical Innovations Raises $10.2 M in Private Placement by Admin-USMI | Sep 21, 2022 | News Release, News Release 2022Takoma Park, MDRead Press...
Canady Cold Helios Plasma Reduces Soft Tissue Sarcoma Viability by Inhibiting Proliferation, Disrupting Cell Cycle, and Inducing Apoptosis: A Preliminary Report by Admin-USMI | Aug 4, 2022 | Cold Plasma, PublicationsTakoma Park, MDRead...
The Granger Causal Effects of Canady Helios Cold Plasma on the Inhibition of Breast Cancer Cell Proliferation by Admin-USMI | May 19, 2022 | Cold Plasma, General, PublicationsTakoma Park, MDRead...
JCRI – ABTS and USMI to Present a Two-year Follow-up of Phase I Clinical Trial Using Cold Atmospheric Plasma for the Treatment of Solid Tumors at Israeli Society of Surgical Oncology by Admin-USMI | May 12, 2022 | News Release, News Release 2022Takoma Park, MDRead Press...
